|Day Low/High||16.72 / 18.50|
|52 Wk Low/High||3.58 / 20.96|
The overall market seems to be mispricing the threats of rapidly increasing prices and the fast-spreading Delta variant.
And It comes after one of the best days of the year for the biotech sector.
Watch Medigen stock, as the Taiwanese president becomes one of the first citizens of the island nation to roll up her sleeve.
Sometimes it's best to move to the sidelines until something changes.
Dynavax Technologies and Albireo Pharma are names for consideration while investors wait for sentiment on the biotech sector to eventually turn around.
Dynavax Technologies, Kala Pharmaceuticals and TherapeuticsMD are three names this biotech investor plans to add exposure to via covered calls.
Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.
Dynavax Technologies and Omeros Corp. have tested shareholders' patience over time and again are at inflection points.
The three either have made recent progress toward advancing products in their pipelines or have caught the eye of analysts.
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
Few parts of this biotech space are more frustrating that what I have dubbed 'Tier 3' biotech concerns.
Quick takes on fourth-quarter results from these 3 biotech names.
Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
I continue to see these names as bargains in the biotech and biopharma space.
These names are moving up or down in a big way ahead of releasing drug-trial results.
American Society of Clinical Oncology will see presentations from dozens of companies.
After a strong week for the biotech sector, these names have potential catalysts to move shares.
Data and industry conferences will likely be catalysts for shares in the space.
Your questions are answered in our latest addition of the biotech mailbag.
Here are a few key events I will be watching closely for in the months ahead on stocks I think are buys at current levels.
A roundup of biotech names with actions pending at the FDA in coming weeks.
Readers have asked about Acadia Pharmaceuticals and Dynavax Technologies, so we answer.